exclude gingival epithelium from the root surface and provide physical space for the ingrowth of the desired tissues.
These barrier membranes can serve as substrates for biofilm formation. Premature membrane exposure is common in GTR procedures and results in microbial colonization of the membrane (Garrett, 1996) . It is worthwhile to review the effects of such membrane exposure upon regenerative outcomes for better elucidation of the effects of indolent infections on bone healing. Non-resorbable membranes are rapidly colonized with periodontal pathogens following surgical placement (Sbordone et al., 2000) . Many investigators have reported that such exposure is associated with poor regenerative outcomes, which may be clinically significant (Nowzari and Slots, 1994; Nowzari et al., 1995; Sander and Karring, 1995; Trombelli et al., 1995; Smith MacDonald et al., 1998; Yoshinari et al., 1998) .
Membrane colonization may be a greater problem when multiple deep pockets are present during healing. Nowzari et al. reported that a group of patients who had all pockets surgically reduced to 5 mm or less had better outcomes than those with persistent deep pockets (Nowzari et al., 1996) . The authors suggest that the persistent pockets served as bacterial reservoirs, thereby facilitating microbial colonization of the membranes.
Anti-infective Interventions and regenerative Outcomes
The extent to which antimicrobial interventions improve regenerative outcomes provides additional evidence of the effect of infection upon tissue regeneration.
Antibiotics have been applied to barrier materials, which has often resulted in increased attachment gain (Pepelassi et al., 1991; DiBattista et al., 1995; Zarkesh et al., 1999; Zucchelli et al., 1999; Yoshinari et al., 2001) . Systemic antibiotics have also been shown to improve regenerative outcomes (i.e., GTR) (Nowzari et al., 1995) . Some antimicrobial agents affect connective tissue metabolism through mechanisms unrelated to their effects on bacteria, however (e.g., the effects of tetracyclines on some matrix metalloproteinases) (Ryan and Golub, 2000; Sorsa et al., 2006) . As a result, data involving the use of some antimicrobial agents (e.g., tetracycline and its congeners) must be interpreted with caution.
In orthopedic surgery, antibiotics have been used to improve surgical outcomes. Various vehicles have been used to deliver antibiotics to surgical sites, and have exhibited favorable release kinetics (Mousset et al., 1995; Benoit et al., 1997) . This group also reported that the release of vancomycin could be delayed by the coating of the calcium sulfate with a polymer. Moojen et al. found that tobramycin loading of a biomimetic HA coating on a titanium rod resulted in reduced infection and increased implant stability in a rabbit tibia model in which test sites were infected with Staphylococcus aureus prior to implantation (Moojen et al., 2009) . Covalent attachment and controlled release of vancomycin from titanium rods have also been shown to reduce peri-prosthetic infection and related osteolysis (Antoci et al., 2007a (Antoci et al., ,b,c, 2008 Edupuganti et al., 2007; Adams et al., 2009) .
In summary, ample evidence exists to suggest an association between infection and suboptimal regenerative outcomes. Presumably, this effect is mediated via the tissue-destructive aspects of the inflammatory response.
MEchAnIstIc cOnsIDErAtIOns
An understanding of the mechanisms by which inflammation causes tissue destruction is helpful in understanding the interface between inflammation and regeneration. The effects of inflammation upon bone healing are the result of the actions of various mediators and are reviewed below.
Arachidonic Acid Metabolites
Arachidonic acid (AA) metabolites have been associated with periodontal attachment loss, especially prostaglandin E 2 , or PGE 2 (Offenbacher et al., 1984 (Offenbacher et al., , 1990 (Offenbacher et al., , 1993 Preshaw and Heasman, 2002; Kirkwood et al., 2006; Nisengard et al., 2006) . Given the association of PGE 2 with periodontal tissue destruction and bone loss, it seems logical to suggest that the presence of PGE 2 would be inimical to bone formation. The evidence is compelling on the molecular/mechanistic level, since PGE 2 is a potent mediator of bone resorption. This is due, in part, to a positive effect on osteoclastogenesis by promotion of the expression of RANKL and the inhibition of osteoprotegerin (OPG) (Raisz, 1999; Horowitz et al., 2005) . Non-steroidal antiinflammatory drugs (NSAIDs), which interfere with PGE 2 synthesis, may slow the rate of periodontal destruction (Williams et al., 1985 (Williams et al., , 1989 Jeffcoat et al., 1988; Weber et al., 1994; Paquette et al., 1997; Salvi and Lang, 2005) .
Thus, it seems that inhibitors of prostaglandin synthesis (viz., NSAIDs) would be likely to promote bone regeneration. As a result of this premise, new local delivery forms of NSAIDs have been developed to enhance periodontal and bone regeneration (Harten et al., 2005; Reynolds et al., 2007) .
However, the literature supporting this assertion is ambiguous and contradictory. Although PGE 2 has been shown to stimulate bone resorption, prostaglandins have also been shown to inhibit osteoclast function (Fuller and Chambers, 1989; Chambers et al., 1999) . Administration of cyclo-oxygenase (COX) inhibitors (i.e., NSAIDs) impairs fracture healing in a dose-dependent manner (Harder and An, 2003; Gerstenfeld et al., 2007; Vuolteenaho et al., 2008) . This effect has been demonstrated for a variety of NSAIDs, including indomethacin (Allen et al., 1980; Keller et al., 1987; Dimar et al., 1996) , ibuprofen (Lindholm and Tornkvist, 1981; Tornkvist et al., 1984; Obeid et al., 1992) , ketorolac (Glassman et al., 1998; Martin et al., 1999) , and celecoxib (Bergenstock et al., 2005; Leonelli et al., 2006; Simon and O'Connor, 2007) . It may be worth noting that eicosanoids other than PGE 2 may affect bone metabolism, including prostacyclin (PGI 2 ) (Nakalekha et al., 2010) and leukotrienes (Cottrell and O'Connor, 2009; Wixted et al., 2009 ). However, relatively little literature exists on this topic.
cytokines
Cytokines involved in the inflammatory response include (but are not limited to) IL-1, IL-6, IL-11, IL-18, and TNF-α (Havemose-Poulsen and Holmstrup, 1997; Horowitz et al., 2005; Graves, 2008) . These cytokines are released in a "temporally and spatially controlled manner" (Gerstenfeld et al., 2003; Mountziaris and Mikos, 2008) . Inflammatory cells are then recruited to the site, and angiogenesis occurs (Gerstenfeld et al., 2003; Rosenberg, 2005) . Dependent upon the site, osteoprogenitor cells may also undergo differentiation and proliferation (Dimitriou et al., 2005) .
The signals, such as TNF-α, IL-1, and IL-6, are critical for the inflammatory response that triggers osteogenesis. TNF-α, IL-1, and IL-6 are important in this process. IL-1 and TNF-α exhibit a biphasic response, with high levels expressed immediately following injury that become undetectable within 72 hours. At approximately 3 to 4 weeks post-injury, both IL-1 and TNF-α exhibit peaks which may correspond to early phases of the remodeling process .
Gerstenfeld et al. demonstrated that bone healing was delayed in TNF-α-receptor-deficient mice (Gerstenfeld et al., 2001) . TNF-α regulates both osteoblasts and osteoclasts by means of the TNFR1 and TNFR2 cell-surface receptors, the latter of which is expressed only following injury and may be responsible for promoting bone formation Balga et al., 2006) . TNF-α-receptor-deficient mice exhibit decreased osteoclastogenesis in response to bacterial challenge, thus implicating TNF in this process . IL-1 and TNF-α play similar roles in these processes via different signaling pathways (Nanes and Pacifici, 2005) . IL-1 (both α and β forms) binds to IL-1R/Toll-like receptors, which activate interleukin-receptor-associated kinase-1 (IRAK-1); IRAK-1 may activate NF-κB (Janssens and Beyaert, 2003) .
NF-κB is well-established as essential for osteoclastogenesis (Boyce et al., 1999) . Boyce et al. showed that mice deficient in functional NF-κB developed a condition akin to osteopetrosis due to the absence of osteoclasts. Recently, NF-κB has also been shown to affect bone formation through an effect on osteoblastic function (Chang et al., 2009 ). More specifically, Chang et al., reported that inhibition of the endogenous inhibitor of kappaB kinase (IKK)-NF-κB in a murine model significantly increased bone mass and bone mineral density. These authors suggest that NF-κB may be an attractive therapeutic target in the treatment of osteoporosis and various inflammatory bone disorders (e.g., periodontitis and arthritis). Such therapy might be particularly efficacious, since inhibition of NF-κB will not only suppress osteoclast-mediated bone resorption, but will also promote osteoblast function and bone formation.
TNF-α and IL-1 have also been shown to inhibit collagen synthesis (Harrison et al., 1998; Horowitz et al., 2005) . IL-1 has been shown to repress promoter activity and collagen synthesis in a dose-related manner (Harrison et al., 1998) . Interestingly, this effect was mitigated by the administration of indomethacin. TNFα inhibits collagen synthesis in vitro, in addition to its previously mentioned effects on bone resorption (Bertolini et al., 1986) .
IL-6 regulates osteoblast and osteoclast differentiation, influences the expression of vascular endothelial growth factor, and promotes callus mineralization and maturation (Horowitz et al., 2005; Yang et al., 2007) . Mice deficient in IL-6 exhibit less bone loss on challenge from P.g. than do wild-type mice (Baker et al., 1999) . IL-6 has been shown to overcome inhibition of GM-CSF inhibition of osteoclast differentiation in vitro, as does TNF-α (Gorny et al., 2004) . However, mice deficient in gp-130 activator protein showed increased numbers of osteoclasts (Kawasaki et al., 1997) . Because IL-6 shares this protein in the receptor complex (Manolagas et al., 1995) , other members of this family may be responsible for the effects observed by Kawasaki et al. Blanchard et al. have noted that the actions of IL-6 on bone are like a "double-edged sword" in that this cytokine can promote either bone formation or resorption, depending on the context (Blanchard et al., 2009 ).
nitric Oxide
Nitric oxide (NO) is another inflammatory mediator that has been shown to have a paradoxical relationship with bone. For example, although excessive production of NO may be associated with bone loss in some inflammatory conditions, NO also mediates some of the beneficial effects of estrogen on bone via the NO/cyclic guanosine monophosphate (cGMP) pathway (Wimalawansa, 2008 . Knockout mice deficient in endothelial nitric oxide synthase (eNOS) exhibit osteoporosis as a result of a defect in bone formation (van't Hof and Ralston, 2001) . Similarly, mice that are deficient in inducible NOS (iNOS) exhibit altered bone healing (Saura et al., 2010) . Increased bone mineral density has been reported in mice deficient in all three isoforms of NOS (Sabanai et al., 2008) . The transcription factor Cbfa-1 and the mitogen-activated protein kinase (MAPK) pathway are crucial for osteoblastic cell differentiation, and NO plays a significant role in this process (Zaragoza et al., 2006) . NO inhibition delays remodeling of an autogenous bone graft (Diwan et al., 2010) and also modulates bone loss subsequent to apical periodontitis infection (Fukada et al., 2008) .
NO is implicated in inflammation-related bone loss. Mice lacking iNOS exhibited no maxillary bone loss on challenge with Porphyromonas gingivalis, while the wild-type mice did (Gyurko et al., 2005) . In vitro, iNOS-deficient cells developed 51% fewer osteoclast-like cells than did the wild-type. The authors concluded that iNOS promotes bone resorption during bone development as well as after bacterial infection, and that it is involved in osteoclast differentiation. Other workers have shown that iNOS is also involved in the pathogenesis of inflammationmediated osteoporosis (Armour et al., 2001) . Thus, NO also has a paradoxical association with bone metabolism.
growth factors and Morphogens
Chen et al. investigated the effects of recombinant human osteogenic protein-1 (rhOP-1) and bone morphogenetic protein 2 (rhBMP-2) on osteogenesis in a chronically infected site (Chen et al., 2006 (Chen et al., , 2007 . Both proteins maintained their osteoinductivity in the presence of infection, although this property was enhanced by systemic antibiotic therapy, thus suggesting that infection interfered with bone formation. In the infected sites, no substantial callus formation was observed in the absence of either rhOp-1 or rhBMP-2. Infected femoral defects exhibit reduced expression of collagen I and II and osteocalcin mRNAs, as well as BMP receptor II (Brick et al., 2009) . Aseptic inflammation negatively affects the osteoinductivity of BMP-2, which can be mitigated by the utilization of a composite graft composed of BMP-2 and collagen (Ji et al., 2010) .
Pro-inflammatory Disease states and bone healing
Several non-infectious diseases are associated with derangements of bone metabolism. Diabetes has been shown to increase the risk of fracture and is also associated with impaired fracture healing (Schwartz, 2003) . Several of the effects of diabetes are due to the presence of advanced glycation end-products (AGEs). AGEs result from the non-enzymatic reaction between glucosederived precursors and intra-and extracellular proteins. AGEs are capable of binding to a specific receptor (RAGE). RAGE is expressed on various inflammatory cells, and the AGE-RAGE interaction results in the release of pro-inflammatory cytokines, some of which are involved in bone resorption. The potential significance of the AGE-RAGE interaction in the pathogenesis of periodontal bone destruction is underscored by the finding that blockade of RAGE decreased bone loss in P.g.-infected diabetic mice (Lalla et al., 2000) . Additionally, AGEs in bone have been shown to increase osteoclast-mediated bone resorption (Miyata et al., 1997) , inhibit markers of osteoblast activity (Katayama et al., 1996) , and stimulate IL-6 production in bone cells (Takagi et al., 1997) .
Rheumatoid arthritis (RA) is a chronic inflammatory disorder which may affect many organ systems, but its orthopedic manifestations chiefly occur because of its effect on the synovial linings of various joints. RA causes destruction of articular cartilage and bone (an effect that is likely due to an imbalance between pro-and anti-inflammatory cytokines) (McInnes and Schett, 2007) . NF-κB is also believed to play a critical role. T-helper cells, especially the Th17 subset, are believed to be critical in the pathogenesis of RA (Koenders et al., 2006) . Th17 cells produce IL-17, which is a potent inducer of other cytokines (e.g., IL-1 and TNF-α). IL-17 activates NF-κB, which induces the expression of numerous cytokines and chemokines (Brown et al., 2008) . Th17 cells and their hallmark cytokine, IL-17, are likely to prove of seminal importance in understanding the pathogenesis of many inflammatory disorders (reviewed by Weaver et al., 2007; Brown et al., 2008; Gaffen, 2008; Garrett-Sinha et al., 2008) . It has recently been suggested that this newly described subset of cells and their associated cytokine, IL-17, may also be of interest in describing the pathogenesis of periodontal diseases (Gaffen and Hajishengallis, 2008) .
In conclusion, various inflammatory mediators have an ambiguous and somewhat paradoxical relationship with bone formation and healing (see Table) .
rEsOlutIOn Of thE PArADOx
Inflammation and bone resorption are normal antecedents to bone healing. The requirement for bone resorption during bone healing can be inferred from the observation that delayed healing is observed in a setting of impaired osteoclast function or number. Such conditions include osteopetrosis and bisphosphonate-related osteonecrosis of the jaws (BRONJ) (Landa et al., 2007; Del Fattore et al., 2008; Filleul et al., 2010) . Thus, pro-inflammatory cytokines may be necessary for bone repair and regeneration. In particular, IL-1, IL-6, TNF-α, and various eicosanoids (especially PGE 2 ) seem to be required for optimal bone formation. Given the apparent requirement for the presence of pro-inflammatory mediators, why is infection-associated inflammation associated with bone loss and impaired regeneration?
The answer to this paradox can likely be found in the carefully orchestrated sequence of events that occurs during bone healing. A temporal "window" exists immediately subsequent to the tissue insult (e.g., regenerative surgical intervention or a fracture). At this stage, several pro-inflammatory mediators initiate the repair cascade. If these requisite mediators are absent, then bone formation may be impaired (Gerstenfeld et al., 2001) . Inhibition of cyclo-oxygenase, leading to decreased PGE 2 , may explain the impaired bone healing often noted when NSAIDs are given in the early healing phase following various types of orthopedic surgical interventions (Harder and An, 2003; Vuolteenaho et al., 2008) . The effect is reversible, however, and normal strength is eventually attained when the use of COX inhibitors is discontinued (Gerstenfeld et al., 2007) .
In a non-infected surgical site, the initial inflammatory reaction quickly resolves, after which the reparative phase predominates. The resolution of inflammation is not a passive process, but rather it is dependent upon specific chemical mediators, including lipoxins, resolvins, and protectins (Serhan, 2007 (Serhan, , 2009 . These "pro-resolution" molecules, like the proinflammatory eicosanoids, are derivatives of AA. During inflammation, activation of 15-lipoxygenase leads to "class switching" of AA metabolism and subsequent synthesis of these pro-resolution agents. However, in an infected site, the inflammatory response may persist and become chronic. This occurs in periodontal diseases. In the case of regenerative sites, the Induces synthesis of IL-6, GMCSF, and MCS IL-1 (both α and β) binds to IL-1R/Tolllike receptor family, which activates interleukin receptor-associated kinase-1 (IRAK-1); IRAK-1 may activate NF-κB (Janssens and Beyaert, 2003) Promotes collagen synthesis and crosslinking Inhibits collagen synthesis (Horowitz et al., 2005) Enhances synthesis of prostaglandins Stimulates angiogenesis 
IL-6
Promotes callus mineralization and maturation (Yang et al., 2007) Promotes bone resorption (Blanchard et al., 2009) Gp-130 activator protein
Mice lacking gp-130 activator protein have increased osteoclasts; however, this receptor is shared by all members of IL-6 family, so this complicates interpretation of this finding (Kawasaki et al., 1997) Has been shown to cause increase in osteoclastogenesis (Gorny et al., 2004) . Regulates differentiation of progenitor cells into osteoclasts (Horowitz et al., 2005) Promotes bone healing (Blanchard et al., 2009) IL-6-deficient mice showed less bone loss secondary to P.g. challenge than did wild-type mice (Baker et al., 1999) 
TNF-α
Initiates repair cascade Bone formation inhibited via inhibition of osteoblast differentiation, suppression of osteoblast function, and induction of osteoblast resistance to 1,25-(OH)D 3 (Nanes and Pacifici, 2005) TNF-α regulates both osteoblasts and osteoclasts via the TNFR1 and TNFR2 cell-surface receptors Bone healing is delayed in TNF-α receptor-deficient mice (Gerstenfeld et al., 2001) Enhanced osteoclastogenesis and increased protease production by osteoclasts Nanes and Pacifici, 2005) Enhances synthesis of prostaglandins PGE 2 May be needed for normal bone repair (inferred from effect of NSAIDs on fracture healing) Potent stimulator of bone resorption and osteoclastogenesis (Raisz, 1999; Horowitz et al., 2005) Bone resorption may be mediated by c-AMP-dependent mechanism via EP4 receptor (Miyaura et al., 2000) Inhibit osteoclast function (Chambers et al., 1999) Nitric oxide Knockout mice deficient in endothelial nitric oxide synthase (eNOS) exhibit osteoporosis as a result of a defect in bone formation (van't Hof and Ralston, 2001) Increased bone mineral density has been reported in mice deficient in all three isoforms of NOS (Sabanai et al., 2008) Exact mechanisms unknown, but increased bone resorption in iNOS(-/-) mice is correlated with increased expression of receptor activator NF-κB (RANK), stromal-cellderived factor-1 alpha (SDF-1 alpha/ CXCL12), and reduced expression of osteoprotegerin (OPG) (Fukada et al., 2008) Mice deficient in inducible NOS (iNOS) have altered osteogenesis and bone healing (Saura et al., 2010) iNOS-deficient mice did not have bone loss on challenge with P.g., while wild-type mice did (Gyurko et al., 2005) NO inhibition delays remodeling of autogenous bone grafts (Diwan et al., 2010) NO involved with inflammationassociated osteoporosis (Armour et al., 2001) NO-deficient mice have greater osteolysis and inflammatory cell recruitment than do wild-type mice (Fukada et al., 2008) persistent presence of indolent infection and chronic inflammation has a deleterious effect on regeneration. These concepts provide the resolution to the seemingly paradoxical relationship among infection, inflammation, and bone regeneration. Inflammation is needed early in the regenerative process to initiate the repair cascade. If healing occurs normally, then the inflammatory response is resolved promptly and tissue regeneration can occur. If, however, the site becomes infected and the inflammatory response persists and becomes chronic, then an adverse effect on bone formation will likely be observed. The likelihood of chronic infection may be enhanced when materials or devices are implanted into the surgical site, since these provide a substrate for potential microbial colonization. The role of various inflammatory mediators is context-specific with regard to the temporal sequence of the injury-repair continuum.
clInIcAl IMPlIcAtIOns AnD futurE DIrEctIOns
Interventions which interfere with microbial colonization of the surgical site are likely to promote regeneration. Some of these are simple, such as proper aseptic technique during surgery. Some, such as the use of prophylactic antibiotic coverage to enhance bone healing by suppressing indolent infections, should be further investigated. Another concept lies in the idea of submergence of certain regenerative materials (e.g., non-resorbable membranes), although this does not appear necessary in the case of certain titanium implants (Buser et al., 1997 (Buser et al., , 1999 Brocard et al., 2000) .
One simple expedient may be the aggressive treatment of oral foci of infection prior to undertaking any therapy that involves the implantation of any device or material (Nowzari et al., 1996) . This is similar to the periodontal concept of "fullmouth disinfection," in which the entire mouth is treated in a short period of time, to prevent "re-infection" of treated pockets by flora from untreated pockets (Bollen et al., 1998; Koshy et al., 2004; Apatzidou, 2006; Quirynen et al., 2006) .
Certain non-antimicrobial molecular agents may mitigate some of the effects of infection. As noted previously, infection can inhibit expression of collagen I and II and osteocalcin mRNAs, as well as BMP receptor II expression (Brick et al., 2009 ). However, all four genes were up-regulated in infected defects in the presence of rhBMP-2. Delivery of substantial doses of rhBMP-2 and rhOP-1 has also been shown to mitigate the effect of infection, although this effect was more pronounced when an antibiotic was used (Chen et al., 2006) . Although not used in a bone site, it has been shown that catheter-related staphylococcal infections could be reduced by coating the substrate with basic fibroblast growth factor (Hirose et al., 2007) .
Resolution of the inflammatory process appears to be an active process, modulated by various mediators such as lipoxins, resolvins, and protectins, which serve as "stop signals" (Serhan, 2009) . Administration of such agents may permit the therapeutic modulation of the inflammatory process. In vitro studies have shown beneficial effects using lipoxins and resolvins to treat peritonitis and infection with T. gondii and A. costaricensis (Bandeira-Melo et al., 2000; Aliberti et al., 2002a,b; Spite et al., 2009) . Of particular relevance to dental applications, resolvin E1, a "proresolution" molecule derived from omega-3 fatty acids, has been shown to provide protection from periodontitis (Hasturk et al., 2006) .
One problematic area concerns post-operative control of pain and inflammation. NSAIDs are widely prescribed by many surgeons following regenerative interventions in the head and neck. For example, the use of NSAIDs has been part of the postoperative protocol in the University of Kentucky Periodontology Clinic for over a decade, and those outcomes that have been tracked indicate a high level of success (i.e., endosseous implants; unpublished observations). This observation is consistent with a recently reported double-blind randomized clinical trial showing that systemic ibuprofen did not have a significant effect on the marginal bone around dental implants in the early healing period (Alissa et al., 2009 ).
Reconciliation of these positive outcomes with the negative association reported between NSAID use and bone healing in the orthopedic literature is difficult, although the limited duration of such therapy following most dento-alveolar interventions may mitigate the negative effect of NSAIDs on bone healing. Several considerations exist worth noting. First, much of the literature on the deleterious effects of NSAIDs is derived from long-bone fracture models. Second, the healing process may differ somewhat when one is considering the healing of surgical wounds in the membranous bones of the craniofacial region. It is obvious that additional work is needed in this area. Pending more definitive information, however, clinicians may wish to limit the duration and dosage of NSAIDs following surgical implantation in the oral cavity.
suMMArY
The study of the relationship between inflammatory mediators and bone has been aptly termed "osteoimmunology" (Graves, 2008) . The relationship between the host response and bone biology is complex. Inflammation, repair, and regeneration are carefully choreographed processes which occur in a specific temporal and physical context. These processes are modified on an ad hoc basis, as dictated by circumstances such as infection. A better understanding of these associations will allow for the identification of new therapeutic targets and the development of novel interventions to promote bone regeneration.
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